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Background: RNA-binding protein Translocated in LipoSarcoma/FUsed Sarcoma (TLS/FUS) is one of causative
genes for familial amyotrophic lateral sclerosis (ALS). We previously identified that TLS was associated with protein
arginine methyltransferase 1 (PRMT1), and four arginine residues within TLS (R216, R218, R242 and R394) were
consistently dimethylated. Protein arginine methylation is involved in various cellular events such as signal
transduction, transcriptional regulation and protein-protein interactions.
Results: To understand the biological role of arginine methylation of RNA-binding protein, we prepared and
characterized a mouse monoclonal antibody against asymmetric dimethylarginine of TLS. By cloning and screening,
one stable hybridoma cell clone (2B12) producing anti-asymmetric dimethylated TLS on R216 and R218 antibody
was established. The monoclonal antibody 2B12 is specific for the asymmetrically dimethylated arginine peptide
and does not react with the same peptide sequence containing unmodified and symmetrically dimethylated
arginine residues by dot-blot analysis. 2B12 was also validated GST tagged TLS with PRMT1 by in vitro arginine
methylation assays. Since methylated TLS in HeLa cells and mouse and human brain protein extracts was
immunoprecipitated with 2B12, we performed RNA-binding protein immunoprecipitation assays using HeLa cell
lysate and this antibody. We demonstrated that the long noncoding RNA (lncRNA) transcribed from cyclin D1
promoter binds methylated TLS.
Conclusions: A monoclonal antibody that is capable of detecting the methylarginine status of TLS will facilitate the
molecular and cellular analysis of transcriptional regulation by lncRNA through methylated TLS, and can be used as
a favorable tool for clinical diagnosis of ALS caused by TLS dysregulation.
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Translocated in LipoSarcoma/FUsed in Sarcoma (TLS/
FUS) was originally identified in malignant liposarcoma as
a part of the chimeric fusion protein TLS-CHOP [1]. Re-
cently, it was reported that TLS is one of causative genes
for familial amyotrophic lateral sclerosis (ALS) [2,3]. TLS
is also implicated in various cellular programs such as
transcription, RNA processing and DNA repair [4]. We* Correspondence: rkurokaw@saitama-med.ac.jp
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article, unless otherwise stated.have demonstrated that the long noncoding RNAs
(lncRNAs) transcribed from the cyclin D1 (CCND1) pro-
moter (promoter-associated noncoding RNAs: pncRNAs)
bind TLS and inhibit the histone acetyltransferase activities
to repress the transcription of CCND1 gene [5]. Recent
studies reveal that lncRNAs regulate the transcription of
target genes [6]. The precise mechanisms of transcriptional
regulation by lncRNAs, however, are still unclear.
Arginine methylation is one of posttranslational modifica-
tions, and accomplished by protein arginine methyltransfer-
ases (PRMTs). Arginine residues can be monomethylated
or dimethylated, and dimethylation can be both symmetriced Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public





















Figure 1 The monoclonal antibody specificity tested by
dot-blot analysis. (A) Summary of peptide sequences. Three TLS
peptides containing either no modification (Non) or R216/R218me2a
(me2a) or R216/R218me2s (me2s) were synthesized. TLS peptide
containing no modification was used for producing polyclonal
antibody in rabbit, and TLS peptides containing R216/R218me2a or
R216/R218me2s were used for the immunization of mice and
hydridoma development. (B and C) Antibody specificity was tested
by dot-blot analysis. Diluted peptides (B; 0.2, 1, 5 ng, C; 20, 100,
500 ng) were blotted onto the nitrocellulose membrane and the
dot-blotted membranes were incubated with a rabbit polyclonal
antibody A1 (B) or a mouse monoclonal antibody 2B12 (C). Note
that A1 reacted equally with TLS peptides either no modification or
symmetrical or asymmetrical dimethylation, and 2B12 recognized
only TLS peptide containing asymmetrical dimethylated arginines.
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nine (aDMA) is catalyzed by the type I class of PRMTs
(PRMT1, 3, 4, 6 and 8), and symmetric dimethylarginine
(sDMA) is catalyzed by the type II class (PRMT5 and 7). In
regarding to histone arginine modification, H4R3me2a and
H4R3me2s are basically linked to transcriptional activation
and repression, respectively [7,8]. We have shown that TLS
is associated with PRMT1, and four arginine residues
within TLS (R216, R218, R242 and R394) are constitutively
dimethylated [9]. However, the functional role of arginine
methylation of RNA-binding proteins still needs to be stud-
ied. RNA-binding proteins often contain glysine-arginine-
rich motifs and are considered substrates for PRMTs. In
fact, FMRP, EWS, which are also related with diseases, are
dimethylated [10,11]. Therefore, it is believed that methyla-
tion of RNA-binding proteins could influence RNA-protein
and/or protein-protein interactions.
ALS is a fatal neurodegenerative disease caused by de-
generation of motor neurons. Identification of several
mutations in the TLS gene from ALS patients suggested
that disruption of RNA metabolism might be one of key
events in ALS pathogenesis. Interestingly, natural arginine
mutation (R216C), one of methylated arginine we identi-
fied, of TLS from ALS patients was reported [12]. More-
over, it was an interesting report that the RNA-binding
ability of TLS is essential for the neurodegenerative pheno-
type in vivo of mutant TLS although it was unclear
whether direct contact with RNA or through interactions
with other RNA-binding proteins [13]. Taken together,
these findings suggest that arginine methylation of TLS
might play an important role in the lncRNA-dependent
transcriptional regulation and the disruption of RNA bind-
ing could be implicated in the pathogenesis of ALS.
In this study, we attempt to establish hybridoma cell
lines that can stably produce anti-methylated TLS mono-
clonal antibodies. Here we show one monoclonal antibody
(2B12) can specifically recognize arginine-methylation of
TLS. Our generated antibody could detect selectively the
asymmetrically dimethylated TLS by western blotting.
Moreover, 2B12 was suitable for RNA-binding protein im-
munoprecipitation (RIP) assays to show the interplay be-
tween lncRNA and methylated TLS.
Results
Generation of asymmetric dimethylarginine-specific
antibody and antibody specificity
We have recently demonstrated that PRMT1 asymmet-
rically methylates TLS/FUS on arginine (R) residues [9].
Using mass spectrometry, we identified which residues
of TLS are methylated in vivo [9]. To investigate the bio-
logical role of methylated TLS, we attempted to develop
mouse monoclonal antibodies that specifically recog-
nized TLS symmetrically or asymmetrically dimethylated
on R216 and R218. We prepared TLS peptides that werecontained unmodified, symmetrically modified (me2s),
or asymmetrically modified arginines (me2a) at R216
and R218 (Figure 1A). Unmodified peptide was used for
producing polyclonal antibody in rabbits, and the anti-
serum was obtained (hereafter referred as A1). Modified
peptides were used for immunization of mice, and hybrid-
oma clones were screened by enzyme-linked immuno-
sorbent assay (ELISA). We obtained a few positive clones.
The purified antibody (hereafter referred as 2B12) was se-
lected for further analysis. To access antibody specificity,
we tested 2B12 using synthetic peptides by dot-blot ana-
lysis. As shown in Figure 1B, A1 reacts with all of synthe-
sized peptides equally. In contrast, the monoclonal
antibody 2B12 specifically recognizes the asymmetric-
ally methylated peptide and does not react with the
same peptide sequence containing unmodified and sym-
metrically dimethylated arginine residues by dot-blot
analysis (Figure 1C), confirming the specificity of 2B12
for asymmetric arginine methylation of TLS. Unfortu-
nately we were not able to obtain a monoclonal anti-
body for detecting R216/R218me2s in this study.
In vitro methylation of TLS
To validate whether 2B12 can detect methylated TLS,
we performed in vitro methylation assays by incubating
GST tagged TLS (GST-TLS) with protein arginine meth-




















Figure 3 Detection of in vivo methylation of TLS. (A)
Endogenous TLS is methylated in HeLa cells. Cell extracts from HeLa
treated or not with 3 μM of the general methylation inhibitor AdOx
for 24 h were used for immunoprecipitations. The extracts were
immunoprecipitated with rabbit normal IgG or rabbit polyclonal anti-TLS
antibody. The immunoprecipitated TLS were analyzed by western
blotting with 2B12 or mouse monoclonal anti-TLS antibody. The input
lane shows 10% of the protein used in each immunoprecipitation. Note
that TLS methylation was inhibited by AdOx, and 2B12 specifically
recognized methylated TLS. (B) Immunoprecipitation of endogenous
methylated TLS from HeLa cell extracts was performed with 2B12 in the
presence or absence of competing peptides used for immunization.
Bound methylated TLS was eluted with SDS sample buffer resolved by
SDS-PAGE, and analyzed by western blotting with rabbit polyclonal
anti-TLS antibody.
Fujimoto and Kurokawa Cell & Bioscience 2014, 4:77 Page 3 of 6
http://www.cellandbioscience.com/content/4/1/77Western blotting using 2B12 was performed, and the
signal was detected in GST-TLS methylated by PRMT1 in
the presence of S-adenosyl methionine (SAM) (Figure 2).
No signal was observed in the absence of methylation (i.e.
without SAM) (Figure 2). Interestingly, the interaction be-
tween TLS and PRMT1 was enhanced by the methylation
of TLS (Figure 2). These results suggest that 2B12 specific-
ally reacts with TLS methylated by PRMT1 (i.e. asymmet-
rical dimethylation), and methylation of TLS may effect
protein-protein interactions.
TLS is arginine methylated in HeLa cells
To examine whether 2B12 can detect methylated TLS
in vivo, we carried out immunoprecipitation (IP) experi-
ments on HeLa cells. We should note that TLS was not
immunoprecipitated with a rabbit polyclonal antibody
A1 (data not shown). Thus, we used a rabbit polyclonal
anti-TLS antibody commercially available. To verify the
specificity of 2B12, HeLa cells were treated with a meth-
yltransferase inhibitor adenosine-2’,3’-dialdehyde (AdOx)
(3 μM) for 24 hours. Reduced recognition of TLS by
2B12 was observed for the AdOx-treated cell extracts,
indicating that the treatment significantly reduced TLS
methylation and 2B12 specifically recognized methylated
TLS (Figure 3A). Somehow unmethylated TLS was
immunoprecipitated with TLS polyclonal antibody effi-
ciently although the expression levels of TLS were al-
most same between control and AdOx-treated cells
(Figure 3A). We also assessed if 2B12 could immunopre-






Figure 2 In vitro methylation of the recombinant GST-TLS.
GST-TLS was in vitro methylated using PRMT1 in the presence or
absence of SAM (20 μM). Reaction products were analyzed by
SDS-PAGE followed by western blotting with the indicated antibodies:
anti-GST (top), 2B12 (middle), and anti-PRMT1 (bottom). Note that 2B12
specifically reacts with TLS methylated by PRMT1 only in the presence
of SAM, and methylated TLS strongly associates with PRMT1.of 2B12, peptide inhibition assays were done. Cell ex-
tracts were immunoprecipitated with 2B12 in the pres-
ence of competing peptides used for immunization as
shown in Figure 1A, and the presence of TLS was re-
vealed using an anti-TLS polyclonal antibody. The immu-
noprecipitation of 2B12 was clearly inhibited by the excess
of R216/R218me2a peptide in a dose-dependent manner,
not by other peptides (Figure 3B and Additional file 1), in-
dicating that a monoclonal antibody 2B12 specifically
immunoprecipitated asymmetrically dimethylated TLS.
These results suggest that 2B12 can be valuable to identify
and investigate methylated TLS in vivo.
Assessment of antibody suitability for
immunoprecipitation and RIP assays
The antibody for detecting methylated TLS may be a
valuable tool for analyzing the ALS pathogenesis caused
by TLS dysregulation using IP and the function of TLS
methylation in vivo using RNA-binding protein immuno-
precipitation (RIP) assays. We have shown that TLS binds
the lncRNAs transcribed from CCND1 promoter (CCND1
Input IgG 2B12 Water
CCND1-pncRNA-D
M
Figure 5 Methylated TLS binds CCND1-pncRNA-D. RIP lysate
from HeLa cells were immunoprecipitated using either 2B12 or a
normal mouse IgG as a negative control. RNA associated with
methylated TLS was purified, and validated by RT-PCR using the
specific primers for CCND1-pncRNA-D. The PCR prodcuts were ran
on an agarose gel to detect the presence of CCND1-pncRNA-D. The
“input” omits the immunoprecipitation step, “IgG” used an IgG
antibody for the immunoprecipitation, “2B12” used a 2B12 antibody
to pull down methylated TLS, and “water” lane served as a negative
control for the PCR reaction. The expected size of PCR product for
CCND1-pncRNA-D could be detected in 2B12 RIP. PCR product was
observed in the 10% input and not in the normal mouse IgG RIP.
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of TLS for RNA-protein interactions needs to be studied.
RIP assay is a powerful technique for studying RNA-
binding proteins and their RNA partners. We demon-
strated the specificity of 2B12 in Figures 1, 2 and 3. Thus,
we carried out IP assays using mouse and human brain
samples. 2B12 was able to specifically precipitate methyl-
ated TLS from mouse and human brain extracts (Figure 4).
We further examined RIP assays using 2B12 for detecting
the interplay between methylated TLS and lncRNA. RIP
was conducted using HeLa cell lysate and either 2B12
or normal mouse IgG. Purified RNA was then analyzed
by RT-PCR using the specific primers for the D region
of CCND1 pncRNA (CCND1-pncRNA-D). As shown in
Figure 5, PCR product was observed in the input and not
in the normal mouse IgG RIP. CCND1-pncRNA-D could
be detected in 2B12 RIP by RT-PCR, suggesting that
CCND1-pncRNA-D binds methylated TLS in vivo.
Discussion/conclusions
We previously demonstrated that CCND1 pncRNAs bind
to TLS and inhibit the histone acetyltransferase activities
to repress the transcription of CCND1 gene [5]. We also
identified that four arginine residues within TLS (R216,
R218, R242 and R394) were consistently dimethylated by a
mass spectrometry [9]. These results suggest that arginine
methylation of TLS could have an important role for the
transcriptional regulation by lncRNA.
In this study, we attempted to establish hybridoma cell
lines that can stably produce anti-methylated TLS mono-
clonal antibodies by hybridoma technique. By cloning and
screening, one mouse monoclonal antibody specific to
dimethylated TLS on R216 and R218 was obtained and
the hybridoma cell line was named as 2B12. The charac-
teristic of 2B12 was confirmed by dot-blot and western
blot analyses (Figures 1 and 2). Methylated TLS is more
associated with PRMT1 by in vitro methylation assays
(Figure 2), suggesting that arginine-methylation of TLS
might affect protein-protein interactions. Recently, manyBA
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Figure 4 2B12 is suitable for immunoprecipitation analysis.
2B12 was used to immunoprecipitate methylated TLS in the total
cell lysate from mouse brain (A) and human brain (B). Bound
methylated TLS was eluted with SDS sample buffer resolved by
SDS-PAGE, and analyzed by western blotting with rabbit polyclonal
anti-TLS antibody. The input lane shows 10% of the protein used in
each immunoprecipitation.proteins have been reported to contain both sDMA and
aDMA [14,15]. It will be possible that TLS is also modified
by the symmetric and asymmetric methylations on the
same arginine residues. Since we did not obtain monoclo-
nal antibodies against symmetrically dimethylated TLS,
further studies will be required to solve this point.
TLS was originally identified as a fusion protein TLS-
CHOP in myxoid liposarcoma [1]. More recently, TLS at-
tracts attention because it was found to be a causative gene
for the familial ALS [2,3]. More than a dozen mutations
were reported in amino acids sequence of TLS [16,17]. It is
interesting to note that R216, one of dimethylated arginine
we identified, is the site of a naturally occurring mutation
associated with ALS [12]. Thus, the posttranslational
modification of TLS might be implicated in the pathogen-
esis of ALS. Since 2B12 was suitable to precipitate methyl-
ated TLS in mouse and human brain samples (Figure 4),
2B12 can be a favorable tool for clinical diagnosis of ALS
and will gain insight into the pathogenesis of ALS caused
by arginine mutations of TLS.
We also verified whether our antibody could be used
for RIP assays. CCND1-pncRNA-D binds methylated
TLS in vivo by RIP using 2B12 (Figure 5), suggesting
that arginine-methylation of TLS can affect RNA-protein
interactions. The antibody for detecting asymmetrical
arginine-specific methylation of TLS can be a valuable
tool for analyzing the function of TLS methylation
in vivo. Further study using 2B12 will uncover the
Fujimoto and Kurokawa Cell & Bioscience 2014, 4:77 Page 5 of 6




Rabbit anti-TLS/FUS antibody (ab70381) was purchased
from Abcam. Mouse monoclonal anti-TLS antibody
(611384) was purchased from BD Biosciences. Rabbit
anti-GST antibody (Z5; sc-459) was purchased from
Santa Cruz Biotechnology. Rabbit anti-PRMT1 antibody
(A33) was purchased from Cell Signaling technology.
Adenosine dialdehyde (Adox, Sigma) was dissolved in
DMSO. Total protein lysate from mouse brain (8–10
weeks) and human brain (66 years old) were obtained
from BioChain Institute Inc (Newark, CA, USA).
Peptide synthesis and antibody preparation
Unmethylated and methylated forms of peptides derived
from TLS/FUS were obtained from Scrum Inc, (Tokyo,
Japan). The sequences of the peptides were identical
except for the presence of symmetric or asymmetric
dimethylated arginine in peptide (See Figure 1A).
Rabbit polyclonal antibody against TLS peptide contain-
ing no modification (named as A1) was produced in
Scrum Inc. The mouse monoclonal antibodies against
TLS peptides containing either R216/R218me2s or R216/
R218me2a were produced in ITM Co. Ltd. (Nagano,
Japan). After the immunization and hydridoma develop-
ment, cells were screened by enzyme-linked immunosorb-
ent assay. One specific antibody against R216/R218me2a
(hybridoma clone; 2B12) was obtained and characterized.
In vitro methylation assay
In vitro methylation reactions were performed as described
previously [9]. Briefly, GST tagged TLS were incubated
with bacterially expressed Strep-tagged PRMT1 lysate in
the presence or absence of SAM (Sigma) for 1 h at 30°C.
Methylation reactions were quenched by the addition of
SDS sample buffer, heated at 100°C for 2 min, and sepa-
rated on SDS-PAGE followed by western blotting analysis.
Dot-blot and western blot analyses
For the dot-blot analysis, one μl of diluted peptide in ster-
ile water was blotted onto the nitrocellulose membrane
(Bio-Rad) and dried. The membrane was then blocked
with freshly prepared PBS containing 5% non-fat milk for
1 h at room temperature with constant agitation. The
membrane was incubated with the primary antibodies
diluted in 1% freshly prepared PBS-milk solution for 1 h
at room temperature. After incubating the membrane with
the secondary antibody (anti-mouse HRP-conjugated IgG,
Dako or anti-rabbit HRP-conjugated IgG, Cell Signaling
technology). Chemiluminescent detection was performed
using SuperSignal West Pico substrate (Thermo Scientific).For western blotting analysis, samples were separated by
SDS-PAGE and the proteins were transferred to a nitrocel-
lulose membrane. The membrane was then blocked similar
to that used in the dot-blot analysis as mentioned above.
Cell culture
HeLa cells were maintained at 37°C in Dulbecco’s modified
Eagle’s medium (DMEM, Nacalai tesque, Tokyo, Japan)
supplemented with 10% fetal bovine serum (Nichirei Biosci-
ences Inc). HeLa cells were treated with AdOx (Sigma) for
24 hours. Cells were lysed in RIPA buffer, and cell lysates
were used for immunoprecipitation experiments.
Immunoprecipitation
Cell extracts from HeLa, mouse brain and human brain
were incubated with appropriate antibodies as indicated.
Antibodies against methylated TLS or normal IgG were in-
cubated with Protein G magnetic Dynabeads (Life tech-
nologies) for 10 min at RT with gentle rotation. The cell
extract was added to the mix and incubated for 10 min at
RT with gentle rotation. Beads were collected and washed
three times with WCE buffer, eluted by adding SDS-sample
buffer. For peptide competition assays, cell extracts were in-
cubated in the presence or absence of competing peptide
with magnetic Dynabeads Protein G. The eluted samples
were analyzed by SDS-PAGE and western blotting.
RNA-binding protein immunoprecipitation assay
To determine whether methylated TLS interacts with
lncRNA, 2B12 was used to pull down methylated TLS, and
then bound RNA was purified and detected the expression
of lncRNA from CCND1 promoter by RT-PCR using spe-
cific primers as published [5]. Magna RIP™ RNA-binding
protein Immunoprecipitation kit (Millipore) was used for
RIP procedures according to the manufacture’s protocol.
The precipitated RNA was subject to cDNA synthesis. The
presence of CCND1-pncRNA-D in the cDNA samples was
detected using PCR primers previously used [5].Additional file
Additional file 1: Immunoprecipitation of endogenous methylated
TLS from HeLa cell extracts was performed with 2B12 in the
presence or absence of competing peptides (No; 100 ng, me2a; 25,
50, 100 ng, me2s; 100 ng). Bound methylated TLS was eluted with
SDS sample buffer resolved by SDS-PAGE, and analyzed by western
blotting with rabbit polyclonal anti-TLS antibody. Note that the
immunoprecipitation of 2B12 was inhibited by the excess of R216/
R218me2a peptide in a dose-dependent manner, not by other peptides.Abbreviations
TLS: Translocated in LipoSarcoma; FUS: FUsed Sarcoma; CCND1: Cyclin D1;
lncRNA: Long noncoding RNA; pncRNA: Promoter-associated ncRNA;
RIP: RNA-binding protein immunoprecipitation; PRMT: Protein arginine
methyltransferase; ALS: Amyotrophic lateral sclerosis; AdOx: Adenosine-2’,3’-
dialdehyde; SAM: S-adenosyl methionine.
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